Trial Profile
A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron 250 µg Subcutaneously Every Other Day With Avonex 30 µg Intramuscularly Once Per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated With Avonex
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Jan 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ABOVE
- Sponsors Bayer
- 05 Jan 2015 New trial record